Immunoglobulin E specific for Quercus macrocarpa pollen allergens (sIgE (Quercus macrocarpa))

Immunoglobulin E (IgE) antibodies specific for Quercus macrocarpa (Bur Oak) pollen allergens are the primary mediators of seasonal allergic reactions to this tree species. These antibodies are produced by B cells upon sensitization to specific oak allergens, most notably Que m 1, which is a member of the pathogenesis-related protein family (PR-10) (WHO/IUIS Allergen Nomenclature, 2023). Once formed, these specific IgE molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to Bur Oak pollen, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes (Galli & Tsai, 2023, Nature Reviews Immunology). This physiological cascade results in the clinical symptoms of allergic rhinitis and allergic asthma. Therapeutic interventions include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT), which aims to induce immunological tolerance and the production of IgG4 blocking antibodies (National Institute of Allergy and Infectious Diseases, 2022).

Other names

Bur oak-specific IgEAnti-Que m 1 IgEQuercus macrocarpa-specific IgEOak pollen-specific IgE

Anti-IgE monoclonal antibodies bind to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Allergen-specific immunotherapy involves the repeated administration of allergen extracts to shift the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated tolerant profile, increasing the production of IgG4 antibodies that compete with IgE for allergen binding.